San Diego Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Tease photo

Persistence Finally Pays Off at Neurocrine Biosciences

The weekend of April 7 was a tense one at the headquarters of Neurocrine Biosciences Inc., where over 300 employees collectively held their breath awaiting word from regulators. A decade-long project was about to make or break the company.

By Brittany Meiling April 13, 2017 1:35 p.m. share »
Tease photo

New Hospital to Meet Challenges, Change

Kaiser Permanente has christened its first new hospital in the San Diego area since 1975, an $850 million facility in Kearny Mesa it says will better integrate care for its 610,000 local members.

By John Cox April 13, 2017 1:31 p.m. share »

Neurocrine's Stock Soars Following FDA Approval of Its Drug Ingrezza

Stock is soaring for San Diego drugmaker Neurocrine Biosciences, which just received a stamp of approval from the U.S. Food and Drug Administration for its lead drug Ingrezza.

By Brittany Meiling April 12, 2017 3:16 p.m. share »

San Diego Behavioral Health Facility Among 6 Being Acquired in $400M Deal

Aurora Behaviorial Health Care San Diego is among six psychiatric hospitals being acquired by Care Capital Properties Inc. in a $400 million deal, the Chicago-based investment company announced.

By Lou Hirsh April 12, 2017 3:14 p.m. share »

Murphy Stepping Down as Organovo CEO; Co. Names Replacement

Keith Murphy, the CEO of San Diego’s 3-D bioprinting company Organovo, is stepping down from his position to “pursue entrepreneurial opportunities,” according to a company statement.

By Brittany Meiling April 11, 2017 4:07 p.m. share »

For Laguna Execs, Failing Fast Led to New $40M Biotech Opportunity

Investors have handed the reins of an out-of-state biotech company — along with $40 million in fresh capital — to the former C-suite of San Diego’s short-lived Laguna Pharmaceuticals.

By Brittany Meiling April 11, 2017 4:06 p.m. share »

ATyr Pharma Adds Tim Coughlin to Its Board of Directors

San Diego drugmaker aTyr Pharma has added Tim Coughlin, a highly-esteemed former biotech executive, to its board of directors.

By Brittany Meiling April 11, 2017 4:01 p.m. share »

Following Merger of Mast Therapeutics And Savara, Stock Will Trade on Nasdaq Capital Market

Mast Therapeutics Inc., a local public biotech that was recently acquired by Austin-based Savara Inc., will be moving its stock from the New York Stock Exchange to Nasdaq as part of the merger.

By Brittany Meiling April 10, 2017 4:04 p.m. share »
Tease photo

Bemer USA Purchases Carlsbad Property for New Headquarters

Bemer USA, which makes medical devices geared to vascular physical therapy, has purchased a Carlsbad industrial and office building for approximately $2.58 million.

By Lou Hirsh April 7, 2017 11:39 a.m. share »
Tease photo

UCSD Research Complex to Use Industry Partnerships as Catalyst for Cures

The University of California, San Diego is bringing the pharmaceutical industry onto its campus, giving entrepreneurs and corporations more access to the university’s market-worthy research and advancing public-private collaboration.

By Brittany Meiling April 7, 2017 10:38 a.m. share »

Sommetrics Completes $12.3M Series B-1 Financing Round

Sommetrics, a medical product company in San Diego, has closed a $12.3 million stock financing round to help bring the company’s products to market.

By Brittany Meiling April 6, 2017 4:07 p.m. share »

Ligand Enters New License and Supply Agreement With Connecticut-Based Co.

Ligand Pharmaceuticals Inc. has agreed to license one of its patented products for use in a Connecticut-based drugmaker’s intravenous medicine believed to helpful in controlling seizures and anxiety.

By John Cox April 6, 2017 4:06 p.m. share »
Tease photo

First Quarter Is A Good One For Many Life Science Cos.

Diego had a solid start to the year, with first-quarter stock prices showing significant growth.

By Brittany Meiling April 6, 2017 1:56 p.m. share »
Tease photo

Licensing Puts Viracta in Good Position

Local biotech Viracta Therapeutics has closed an $18.4 million round of financing and inked a licensing deal with the round’s lead investor, Na|ntKwest.

By Brittany Meiling April 6, 2017 1:25 p.m. share »

Brian Drazba Appointed CFO at MEI Pharma

Anti-cancer drugmaker MEI Pharma Inc. has recruited Brian Drazba to serve as the company’s new chief financial officer.

By Brittany Meiling April 4, 2017 2 p.m. share »